Pfizer paid $400M to dispatch an investor suit over off-label marketing allegations

Last year, Pfizer ($PFE) got a federal judge to toss an investor lawsuit tied to its now-withdrawn pain drug Bextra. But that wasn't the only investor suit raising similar issues--namely that Pfizer's board had not been forthright about marketing allegations involving Bextra and other drugs. When they were made public, those allegations sank Pfizer's shares. Another of those shareholder suits was just days away from trial last quarter when the drugmaker agreed to settle it for $400 million. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.